TY - JOUR
T1 - Available treatment options for dystonia
AU - Alfradique-Dunham, Isabel
AU - Jankovic, Joseph
N1 - Funding Information:
J Jankovic has reciveed research and/or training grants from: Adamas Pharmaceuticals, Inc; Allergan, Inc; Botie Therapies, CHDI Foundation; Civitas/Acorda Therapeutics; Dystonia Coalition; Dystonia Medical Research Foundation; Hoffman-La Roche; Huntington Study group; Kyowa Haako Kirin Pharma, Inc; Medtronic Neuromodulation; Merz Pharmaceuticals; Michael J Fox Foundation for Parkinson Research; Nationa Institutes of Health; Neurocrine Biosciences; NeuroDerm Ltd; Parkinson’s Foundation; Parkinson Study Group; Pfizer, Prothena Biosciences Inc, Psyadon Pharmaceuticals, Inc; Revance Therapeutics, Inc, Sangamo Biosciences, Inc; St Jude Medical; Teva Pharmaceutical Industries Ltd. J Jancovic has servies as a consultant or as an advisory committee member for: Adamas Pharmaceuticals, Inc; Allergan, Inc; Pfizer Inc, Revance Therapeutics, Inc; Teva Pharmaceutical Insustries Ltd. He has also received royalties or other payments from: Cambridge; Elsevier; Future Science Group; Hodder Arnold; Medlink; Neurology; Lippincott Williams ad Wilkins; Wiley-Blackwell. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/9/2
Y1 - 2017/9/2
N2 - Introduction: Dystonia is a neurologic movement disorder characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive, movements, postures, or both. The etiology of dystonia is diverse and it includes genetic and other causes. Since the advent of botulinum toxin and deep brain stimulation, the treatment of dystonia has markedly improved and is still evolving. Areas covered: This review gives a historical overview of the treatment options for dystonia. In the absence of pathogenesis-targeted, disease-modifying therapies, the treatment of dystonia remains symptomatic. Botulinum toxin is the first line treatment for some forms of focal and segmental dystonias. Oral medications, including anticholinergics, baclofen, benzodiazepines and antidopaminergic drugs are used primarily in patients with generalized dystonia. Levodopa is an effective treatment for patients with dopa-responsive-dystonia. The use of deep brain stimulation, intrathecal and intraventricular baclofen, as well as ablative surgeries are options for patients with disabling dystonia refractory to other, less invasive, therapies. Expert opinion: The selected treatment modality should be tailored to the patient`s needs and guided by potential side effects. Refractory cases should be referred to tertiary center for evaluation with a multidisciplinary team and potential surgical treatment.
AB - Introduction: Dystonia is a neurologic movement disorder characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive, movements, postures, or both. The etiology of dystonia is diverse and it includes genetic and other causes. Since the advent of botulinum toxin and deep brain stimulation, the treatment of dystonia has markedly improved and is still evolving. Areas covered: This review gives a historical overview of the treatment options for dystonia. In the absence of pathogenesis-targeted, disease-modifying therapies, the treatment of dystonia remains symptomatic. Botulinum toxin is the first line treatment for some forms of focal and segmental dystonias. Oral medications, including anticholinergics, baclofen, benzodiazepines and antidopaminergic drugs are used primarily in patients with generalized dystonia. Levodopa is an effective treatment for patients with dopa-responsive-dystonia. The use of deep brain stimulation, intrathecal and intraventricular baclofen, as well as ablative surgeries are options for patients with disabling dystonia refractory to other, less invasive, therapies. Expert opinion: The selected treatment modality should be tailored to the patient`s needs and guided by potential side effects. Refractory cases should be referred to tertiary center for evaluation with a multidisciplinary team and potential surgical treatment.
KW - Dystonia
KW - botulinum toxin
KW - deep brain stimulation
UR - http://www.scopus.com/inward/record.url?scp=85028923121&partnerID=8YFLogxK
U2 - 10.1080/21678707.2017.1366309
DO - 10.1080/21678707.2017.1366309
M3 - Review article
AN - SCOPUS:85028923121
VL - 5
SP - 707
EP - 716
JO - Expert Opinion on Orphan Drugs
JF - Expert Opinion on Orphan Drugs
SN - 2167-8707
IS - 9
ER -